LUNSUMIO
As listed in the register: LUNSUMIO 5 MG SOLUCION INYECTABLE
5 mg · solución inyectable
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Mosunetuzumab
- Made by
- Roche Registration Gmbh
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Lunsumio Velo). It describes the substance, not this exact product.
Mosunetuzumab-axgb is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and some healthy B-lineage cells.
In vitro, mosunetuzumab-axgb activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-29
Safety of the active substance
From the US prescribing label for the same active substance (Lunsumio Velo). It describes the substance, not this exact product.
WARNING: CYTOKINE RELEASE SYNDROME Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO VELO.
The most common Grade 3 to 4 laboratory abnormalities (≥ 15%) are decreased lymphocyte count, decreased neutrophil count, and increased uric acid.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Roche Registration Gmbh |
|---|---|
| Active substance | Mosunetuzumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 5 mg |
| Form | solución inyectable |
| Classification | L01FX25 · Cancer treatments and immune-system medicines |
| Route | vía subcutánea |
| Marketed | No — authorised but not currently marketed, according to the register |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | LUNSUMIO 5 MG SOLUCION INYECTABLE |
| Nº Registro | 1221649003 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- concentrado para solución para perfusión2 products
1 MG/ML2
1 MG/ML · 2 companies
- solución inyectable1 products
- 5 mg
- solución para perfusión1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.